Implications on IVF patient care of discarding oocytes affected by smooth endoplasmic reticulum aggregates as recommended by the Alpha/ESHRE consensus

DYSMORPHISMS OF OOCYTES IN ART PROCEDURES. LITERATURE REVIEW

Currentliterature review presents the analysis of results of studies of morphological qualities and anomalies (dysmorphisms) of human oocytes in the field of assisted reproductive technologies. The variety of intracytoplasmic anomalies encountered in the clinical practice of in vitro fertilization, their effect on fertilization, cleavage, implantation frequency, clinical pregnancy rate were described. Moreover, the morphological characteristics of oocyte could be considered to use as biomarkers in predicting the quality of embryos and blastocysts, and further implantation potential.

Live Birth Rates in In vitro Fertilization Cycles with Oocytes Containing Smooth Endoplasmic Reticulum Aggregates and Normal Oocytes

Aims:

The aims of this study were to compare the live birth, embryological and pregnancy outcomes after intracytoplasmic sperm injection (ICSI) in patients who have oocytes with smooth endoplasmic reticulum aggregates (SERa+ cycles) and patients with normal oocytes and to compare the pregnancy outcomes based on the observed frequency of SERa.

Settings and Design:

The current study was a retrospective case record review of patients undergoing ICSI from 2012 to 2016 in a specialty fertility center.

Materials and Methods:

The patients were divided into two groups based on the presence of SERa: patients with at least one oocyte containing SERa (SERa+ cycles) (n = 112) and patients with normal oocytes (n = 839). The primary outcome measure was live birth rate. The secondary outcome measures were fertilization rate, cleavage rate, blastocyst formation rate, clinical pregnancy rate, miscarriage rate, and anomalies in children born.

Results:

Women with SERa+ cycles showed similar live birth rates, fertilization rates, cleavage rates, blastocyst formation rates, clinical pregnancy rates, miscarriage rates, and abnormalities in children compared to women with normal oocytes. A gradual reduction in live birth rates was observed when the percentage of oocytes containing SERa increased. The group containing >50% of oocytes with SERa demonstrated no live births.

Conclusions:

Presence of SERa had no major overall negative impact on key embryological and live birth outcomes. A reduction in the live birth rate with increasing proportion of SERa oocytes was observed, with no live births in the group with >50% or all affected oocytes.

Oocytes affected by smooth endoplasmic reticulum aggregates: to discard or not to discard?

PURPOSE

Oocytes containing smooth endoplasmic reticulum aggregates (SERa) have been associated with reduced fertilization and clinical pregnancy rates as well as compromised neonatal outcomes. It was therefore recommended by an Alpha-ESHRE Consensus to discard oocytes presenting this dysmorphism. The data in the literature are nevertheless conflicting and healthy babies have recently been obtained from affected oocytes. The objectives of this study were to compare clinical outcomes between ICSI cycles with and without oocytes affected by smooth endoplasmic reticulum aggregates and to confirm whether affected oocytes can produce healthy babies.

METHODS

A prospective observational study was performed comparing 714 SERa- ICSI cycles to 112 SERa+ cycles. Among the SERa+ cycles, 518 SERa- oocytes and 213 SERa+ oocytes were analyzed. Fertilization, embryo quality, and pregnancy rates as well as neonatal outcomes were compared between SERa+ and SERa- cycles as well as between SERa+ and SERa- oocytes.

RESULTS

The presence of SERa was not associated with an adverse effect on embryological, clinical or neonatal data for SERa+ cycles and oocytes. Seven healthy babies were born from embryos originating from SERa+ oocytes.

CONCLUSIONS

These results are encouraging and might contribute in the future to a revision of the Alpha-ESHRE Consensus. Larger studies, including a correlation between frequency and size of SERa, clinical outcomes and malformation rates, as well as the follow-up of babies born are nevertheless necessary. In the meantime, the currently conflicting data requires caution when considering transfers of embryos affected by SERa.